- Home
- CRON vs XERS Comparison
CRON vs XERS Comparison
Compare CRON & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | XERS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.8M | 1.0B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRON | XERS |
|---|---|---|
| Price | $2.73 | $6.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 0.04 | 0.01 |
| Revenue | ★ $146,587,000.00 | $49,590,000.00 |
| Revenue This Year | $26.34 | $34.37 |
| Revenue Next Year | $15.53 | $22.86 |
| P/E Ratio | ★ $68.38 | $638.48 |
| Revenue Growth | 24.63 | ★ 142.67 |
| 52 Week Low | $1.84 | $4.30 |
| 52 Week High | $3.43 | $10.08 |
Technical Indicators
Market Signals| Indicator | CRON | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 52.39 |
| Support Level | $2.47 | $6.26 |
| Resistance Level | $2.72 | $6.41 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 39.23 | 38.72 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.